Advanced Enzyme Technologies Ltd (IN:ADVENZYMES)
:ADVENZYMES
Want to see IN:ADVENZYMES full AI Analyst Report?
ADVENZYMES Stock Chart & Stats
₹303.25
-₹1.10(-0.32%)
At close: 4:00 PM EST
₹303.25
-₹1.10(-0.32%)
Day’s Range― - ―
52-Week Range₹251.90 - ₹419.80
Previous CloseN/A
Volume535.87K
Average Volume (3M)13.78K
Market Cap
₹41.75B
Enterprise Value₹40.91B
Total Cash (Recent Filing)₹6.19B
Total Debt (Recent Filing)₹346.54M
Price to Earnings (P/E)24.8
Beta1.21
Next Earnings
Aug 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.7%
Share Statistics
EPS (TTM)13.16
Shares Outstanding111,976,150
10 Day Avg. Volume10,375
30 Day Avg. Volume13,779
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)1.75
Price to Sales (P/S)3.83
P/FCF Ratio23.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)15.5
Revenue Forecast (FY)₹8.54B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExceptionally low leverage and steadily building equity provide durable financial flexibility. This reduces solvency risk, supports continued R&D and capacity spend without external funding, and preserves optionality for opportunistic M&A or cyclical downturns, strengthening long-run resilience.
Cash Generation QualityOperating cash flow consistently exceeding net income indicates solid earnings quality and repeatable cash conversion. Reliable cash generation underpins capex for fermentation capacity, funds dividends or buybacks, and supports reinvestment into product development without needing material debt.
In-house R&D & ManufacturingProprietary R&D and scalable fermentation/manufacturing create a sustainable competitive edge. Owning strain development and production lowers supply risk, accelerates new product commercialization across human, animal and industrial segments, and supports higher-margin, differentiated offerings.
Bears Say
Margin CompressionA trend of margin normalization from earlier peaks indicates pressure from pricing, mix shifts, or rising costs. If durable, this could limit operating profit expansion even with revenue growth, reducing free cash flow leverage and constraining long-term EPS improvement.
Volatile Free Cash Flow GrowthUneven free cash flow growth complicates planning and weakens predictability of reinvestment or shareholder returns. While FCF is positive overall, variability—driven by working capital or cyclical demand—raises execution risk for multi-year expansion projects or consistent payout strategies.
ROE ModerationModerating ROE suggests future growth may be more reliant on incremental organic scale than on improving capital efficiency. Persistent moderation can cap long-term return expansion and indicates the company may face limits to translating revenue growth into proportionally higher shareholder returns.
Advanced Enzyme Technologies Ltd News
ADVENZYMES FAQ
What was Advanced Enzyme Technologies Ltd’s price range in the past 12 months?
Advanced Enzyme Technologies Ltd lowest stock price was ₹251.90 and its highest was ₹419.80 in the past 12 months.
What is Advanced Enzyme Technologies Ltd’s market cap?
Advanced Enzyme Technologies Ltd’s market cap is ₹41.75B.
When is Advanced Enzyme Technologies Ltd’s upcoming earnings report date?
Advanced Enzyme Technologies Ltd’s upcoming earnings report date is Aug 03, 2026 which is in 44 days.
How were Advanced Enzyme Technologies Ltd’s earnings last quarter?
Advanced Enzyme Technologies Ltd released its earnings results on May 09, 2026. The company reported ₹3.84 earnings per share for the quarter, beating the consensus estimate of N/A by ₹3.84.
Is Advanced Enzyme Technologies Ltd overvalued?
According to Wall Street analysts Advanced Enzyme Technologies Ltd’s price is currently Overvalued.
Does Advanced Enzyme Technologies Ltd pay dividends?
Advanced Enzyme Technologies Ltd pays a Quarterly dividend of ₹1.2 which represents an annual dividend yield of 1.7%. See more information on Advanced Enzyme Technologies Ltd dividends here
What is Advanced Enzyme Technologies Ltd’s EPS estimate?
Advanced Enzyme Technologies Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Advanced Enzyme Technologies Ltd have?
Advanced Enzyme Technologies Ltd has 111,976,150 shares outstanding.
What happened to Advanced Enzyme Technologies Ltd’s price movement after its last earnings report?
Advanced Enzyme Technologies Ltd reported an EPS of ₹3.84 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 6.825%.
Which hedge fund is a major shareholder of Advanced Enzyme Technologies Ltd?
Currently, no hedge funds are holding shares in IN:ADVENZYMES
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Advanced Enzyme Technologies Ltd
Advanced Enzyme Technologies Limited, headquartered in Thane, India, is a global company engaged in the research, development, manufacturing, and marketing of enzymes and probiotics. Its operations span India, the United States, Asia, and Europe. The company's diverse enzyme offerings cater to human healthcare, animal nutrition, and an extensive range of food processing sectors, including fruit and vegetable, baking, brewing, malting, grain, protein modification, yeast, dairy, and oils/fats processing, as well as various specialty applications. Beyond food-related uses, it also supplies industrial enzymes for non-food industries like textile processing, leather, pulp and paper production, detergents and cleaning aids, biofuels, and biocatalysis. Founded in 1957, the company was previously known as Advanced Biochemicals Limited before changing its name to Advanced Enzyme Technologies Limited in 2005.
Technical Analysis
Dishman Carbogen Amcis Ltd.
―
Gufic Biosciences Limited
―
Morepen Laboratories Limited
―
RPG Life Sciences Limited
―
―